Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 30
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Broad virus inactivation using inorganic micro/nano-particulate materials

  • Rius-Rocabert, Sergio
  • Arranz-Herrero, Javier
  • Fernández-Valdés, Adolfo
  • Marciello, Marzia
  • Moreno, Sandra
  • Llinares-Pinel, Francisco
  • Presa, Jesús
  • Hernandez-Alcoceba, Rubén
  • López-Píriz, Roberto
  • Torrecillas, Ramón
  • García, Antonia
  • Brun, Alejandro
  • Filice, Marco
  • Moya, José S.
  • Cabal, Belen
  • Nistal-Villan, Estanislao
Inorganic materials can provide a set of tools to decontaminate solid, liquid or air containing viral particles. The use of disinfectants can be limited or not practical in scenarios where continuous cleaning is not feasible. Physicochemical differences between viruses raise the need for effective formulations for all kind of viruses. In the present work we describe two types of antimicrobial inorganic materials: i) a novel soda-lime glass (G3), and ii) kaolin containing metals nanoparticles (Ag or CuO), as materials to disable virus infectivity. Strong antiviral properties can be observed in G3 glass, and kaolin-containing nanoparticle materials showing a reduction of viral infectivity close to 99% in the first 10 ​min of contact of vesicular stomatitis virus (VSV). A potent virucidal activity is also present in G3 and kaolin containing Ag or CuO nanoparticles against all kinds of viruses tested, reducing more than 99% the amount of HSV-1, Adenovirus, VSV, Influenza virus and SARS-CoV-2 exposed to them. Virucidal properties could be explained by a direct interaction of materials with viruses as well as inactivation by the presence of virucidal elements in the material lixiviates. Kaolin-based materials guarantee a controlled release of active nanoparticles with antiviral activity. Current coronavirus crisis highlights the need for new strategies to remove viruses from contaminated areas. We propose these low-cost inorganic materials as useful disinfecting antivirals in the actual or future pandemic threats.
Repisalud
Publicación Artículo científico (JournalArticle)

Identification of small molecules capable of enhancing viral membrane fusion

  • García-Murria, Mª Jesús
  • Gadea-Salom, Laura
  • Moreno, Sandra
  • Rius-Salvador, Marina
  • Zaragoza, Oscar
  • Brun, Alejandro
  • Mingarro, Ismael
  • Martínez-Gil, Luis
Several approaches have been developed to analyze the entry of highly pathogenic viruses. In this study, we report the implementation of a Bimolecular Multicellular Complementation (BiMuC) assay to safely and efficiently monitor SARS-CoV-2 S-mediated membrane fusion without the need for microscopy-based equipment. Using BiMuC, we screened a library of approved drugs and identified compounds that enhance S protein-mediated cell-cell membrane fusion. Among them, ethynylestradiol promotes the growth of SARS-CoV-2 and Influenza A virus in vitro. Our findings demonstrate the potential of BiMuC for identifying small molecules that modulate the life cycle of enveloped viruses, including SARS-CoV-2.
Repisalud
Publicación Artículo científico (JournalArticle)

COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.

  • García-Arriaza, Juan
  • Garaigorta, Urtzi
  • Pérez, Patricia
  • Lázaro-Frías, Adrián
  • Zamora, Carmen
  • Gastaminza, Pablo
  • Del Fresno, Carlos
  • Casasnovas, José M
  • Sorzano, Carlos Óscar S
  • Sancho, David
  • Esteban, Mariano
Vaccines against SARS-CoV-2, the causative agent of the COVID-19 pandemic, are urgently needed. We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein (MVA-CoV2-S); their immunogenicity was evaluated in mice using DNA/MVA or MVA/MVA prime/boost immunizations. Both vaccines induced robust, broad and polyfunctional S-specific CD4+ (mainly Th1) and CD8+ T-cell responses, with a T effector memory phenotype. DNA/MVA immunizations elicited higher T-cell responses. All vaccine regimens triggered high titers of IgG antibodies specific for the S, as well as for the receptor-binding domain; the predominance of the IgG2c isotype was indicative of Th1 immunity. Notably, serum samples from vaccinated mice neutralized SARS-CoV-2 in cell cultures, and those from MVA/MVA immunizations showed a higher neutralizing capacity. Remarkably, one or two doses of MVA-CoV2-S protect humanized K18-hACE2 mice from a lethal dose of SARS-CoV-2. In addition, two doses of MVA-CoV2-S confer full inhibition of virus replication in the lungs. These results demonstrate the robust immunogenicity and full efficacy of MVA-based COVID-19 vaccines in animal models and support its translation to the clinic.IMPORTANCE The continuous dissemination of the novel emerging SARS-CoV-2 virus, with more than 78 million infected cases worldwide and higher than 1,700,000 deaths as of December 23, 2020, highlights the urgent need for the development of novel vaccines against COVID-19. With this aim, we have developed novel vaccine candidates based on the poxvirus modified vaccinia virus Ankara (MVA) strain expressing the full-length SARS-CoV-2 spike (S) protein, and we have evaluated their immunogenicity in mice using DNA/MVA or MVA/MVA prime/boost immunization protocols. The results showed the induction of a potent S-specific T-cell response and high titers of neutralizing antibodies. Remarkably, humanized K18-hACE2 mice immunized with one or two doses of the MVA-based vaccine were 100% protected from SARS-CoV-2 lethality. Moreover, two doses of the vaccine prevented virus replication in lungs. Our findings prove the robust immunogenicity and efficacy of MVA-based COVID-19 vaccines in animal models and support its translation to the clinic.
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Multilateral benefit-sharing from digital sequence information will support both science and biodiversity conservation

  • Scholz, Amber Hartman
  • Freitag, Jens
  • Lyal, Christopher H. C.
  • Sara, Rodrigo
  • Cepeda, Martha Lucía
  • Cancio Uriarte, Ibon
  • Sett, Scarlett
  • Hufton, Andrew Lee
  • Abebaw, Yemisrach
  • Bansal, Kailash
  • Benbouza, Halima
  • Boga, Hamadi Iddi
  • Brisse, Sylvain
  • Bruford, Michael W.
  • Clissold, Hayley
  • Cochrane, Guy
  • Coddington, Jonathan A.
  • Deletoille, Anne-Caroline
  • García Cardona, Felipe
  • Hamer, Michelle
  • Hurtado Ortiz, Raquel
  • Miano, Douglas W.
  • Nicholson, David
  • Oliveira, Guilherme
  • Ospina Bravo, Carlos
  • Rohden, Fabian
  • Seberg, Ole
  • Segelbacher, Gernot
  • Shouche, Yogesh
  • Sierra, Alejandra
  • Karsch-Mizrachi, Ilene
  • da Silva, Jessica
  • Hautea, Desiree M.
  • da Silva, Manuela
  • Suzuki, Mutsuaki
  • Tesfaye, Kassahun
  • Tiambo, Christian Keambou
  • Tolley, Krystal A.
  • Varshney, Rajeev
  • Zambrano, María Mercedes
  • Overmann, Jörg
Open access to sequence data is a cornerstone of biology and biodiversity research, but has created tension under the United Nations Convention on Biological Diversity (CBD). Policy decisions could compromise research and development, unless a practical multilateral solution is implemented., This workwas funded by the German Federal Ministry of Education and Research (BMBF) WiLDSI 031B0862 (A.H.S., J.O., and J.F.) and Horizon Europe EVA-GLOBAL 871029 (A.H.S.). I.K.M. was supported by the National Center for Biotechnology Information of the National Library of Medicine, National Institutes of Health.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Modeling the Number of People Infected With SARS-COV-2 From Wastewater Viral Load in Northwest Spain

  • Vallejo, J. A.
  • Trigo Tasende, Noelia
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • López-Oriona, Ángel
  • Barbeito, Inés
  • Vaamonde, Manuel
  • Tarrío-Saavedra, Javier
  • Reif López, Rubén
  • Ladra, Susana
  • Rodiño-Janeiro, Bruno Kotska
  • Nasser-Ali, Mohammed
  • Cid, Ángeles
  • Veiga, María Carmen
  • Acevedo, Antón
  • Lamora, Carlos
  • Bou, Germán
  • Cao, Ricardo
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] The quantification of the SARS-CoV-2 RNA load in wastewater has emerged as a useful tool to monitor COVID–19 outbreaks in the community. This approach was implemented in the metropolitan area of A Coruña (NW Spain), where wastewater from a treatment plant was analyzed to track the epidemic dynamics in a population of 369,098 inhabitants. Viral load detected in the wastewater and the epidemiological data from A Coruña health system served as main sources for statistical models developing. Regression models described here allowed us to estimate the number of infected people (R2 = 0.9), including symptomatic and asymptomatic individuals. These models have helped to understand the real magnitude of the epidemic in a population at any given time and have been used as an effective early warning tool for predicting outbreaks in A Coruña municipality. The methodology of the present work could be used to develop a similar wastewater-based epidemiological model to track the evolution of the COVID–19 epidemic anywhere in the world where centralized water-based sanitation systems exist., This work was supported by EDAR Bens S.A., A Coruña, Spain [grant references INV04020, INV12120 and INV05921 to MP], the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 funded by the ISCIII, Spain - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant numbers PI15/00860 to GB, PI17/01482 and PI20/00413 to MP], the GAIN, Xunta de Galicia, Spain [grant number IN607A 2016/22 to GB, ED431C-2016/015 and ED431C-2020/14 to RC, ED431C 2017/58 to SL, ED431G 2019/01 to RC and SL, and ED431C 2017/66 to MCV], MINECO, Spain [grant number MTM2017-82724-R to RC], Ministerio de Ciencia e Innovación, Spain [grant number PID2020-113578RB-100 to RC], and the Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006 to GB]. The work was also supported by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 - Research and Innovation Framework Programme under grant agreement no 871029. SR-F was financially supported by REIPI RD16/0016/006, KC-P by IN607A 2016/22 and the Spanish Association against Cancer (AECC) and JAV by IN607A 2016/22. Funding for open access charge: Universidade da Coruña/CISUG, EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2017/58, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; ED431C 2017/66
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Building-Scale Wastewater-Based Epidemiology for SARS-CoV-2 Surveillance at Nursing Homes in A Coruña, Spain

  • Trigo Tasende, Noelia
  • Vallejo, J. A.
  • Rumbo-Feal, Soraya
  • Conde-Pérez, Kelly
  • Nasser-Ali, Mohammed
  • Tarrío-Saavedra, Javier
  • Barbeito, Inés
  • Cao, Ricardo
  • Ladra, Susana
  • Bou, Germán
  • Poza, Margarita
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Wastewater-based epidemiology (WBE) has become an effective tool in the surveillance of infectious diseases such as COVID-19. In this work, we performed a brief study of monitoring the SARS-CoV-2 viral load in wastewater from six nursing homes located in the metropolitan area of A Coruña (Spain) between December 2020 and March 2021. The main objective was to detect SARSCoV- 2 outbreaks among residents and study the efficacy of the vaccination campaign. SARS-CoV-2 viral load (RNA copies per L of wastewater) was determined by reverse-transcription quantitative PCR (RT-qPCR) using the quantification cycle (Cq) values for the nucleocapsid (N) gene. Our results showed that the increase in viral load preceded the increase in clinical cases, favoring an early warning system that detects COVID-19 outbreaks in advance, making it possible to contain and stop the transmission of the virus among residents. In addition, the efficacy of the new COVID-19 vaccines was evidenced, since after the vaccination campaign in nursing homes in A Coruña, it was observed that many residents did not present any symptoms of the disease, although they excreted high amounts of virus in their feces. WBE is a cost-effective strategy that should be implemented in all cities to prevent new emerging diseases or future pandemic threats., EDAR Bens S.A.; INV04020, EDAR Bens S.A.; INV12120, EDAR Bens S.A.; INV05921, EDAR Bens S.A.; INV148721, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431C-2016/015, Xunta de Galicia; ED431C-2020/14, Xunta de Galicia; ED431C 2021/53, Xunta de Galicia; ED431G 2019/01, Xunta de Galicia; COV20/00604, Funding for open access charge: Universidade da Coruña/CISUG. This work was mainly supported by the grant INV00821 from Consellería de Política Social (Xunta de Galicia, Spain) to M.P. The team was also supported by EDAR Bens S.A., A Coruña, Spain (grant references INV04020, INV12120, INV05921, and INV148721 to M.P.), by the National Plan for Scientific Research, Development and Technological Innovation funded by the Institute of Health Carlos III (ISCIII), Spain—General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe” [grant references PI15/00860 to G.B., PI17/01482 and PI20/00413 to M.P.], by the Galician Innovation Agency (GAIN) (Xunta de Galicia, Spain) [grant references IN607A 2016/22 to G.B., ED431C-2016/015 and ED431C-2020/14 to R.C., ED431C 2021/53 to S.L., and ED431G 2019/01 and COV20/00604 to R.C. and S.L., by the Ministry of Economic Affairs and Digital Transformation (MINECO), Spain (grant references MTM2017-82724-R to R.C.), by the Spanish Network of Research in Infectious Diseases (CIBERINFEC, ISCIII, reference CB21/13/00055), and by the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 871029. S.R.-F. was financially supported by REIPI RD16/0016/006, K.C.-P. by IN607A 2016/22 and the Spanish Association against Cancer (AECC), and J.A.V. by IN607A 2016/22.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Seroprevalence of toscana Virus and sandfly fever sicilian virus in European bat colonies measured using a neutralization test

  • Ayhan, Nazli
  • López-Roig, Marc
  • Monastiri, Abir
  • Charrel, Rémi N.
  • Serra Cobo, Jordi
Toscana phlebovirus (TOSV) and Sicilian phlebovirus (SFSV) are endemic in the Mediterranean area where they are transmitted to humans by infected sandflies. Vertebrates of several species have been postulated to act as reservoirs of these viruses, but convincing evidence is still awaited. Among them, bats have been suggested, however documented evidence is lacking. Here we tested a total of 329 bats belonging to eight species collected from twelve localities in southern Spain for the presence of neutralizing antibodies specific to TOSV and SFSV. Positive sera were detected in Schreiber's long-fingered bat (Miniopterus schreibersii), mouse-eared Myotis (Myotis myotis), European free-tailed bat (Tadarida teniotis), and common serotine (Eptesicus serotinus) with the latter showing the highest prevalence rates for SFSV (22.6%) and TOSV (10%). There was no difference between females and males. Results suggest that bats are not likely to play a major role in the natural cycle of these two sandfly-borne phleboviruses. However, large breeding colonies of bats can be used as sentinels for surveillance of the presence of such viruses in a given locality. In addition, capture-recapture studies should be initiated in order to understand better the dynamics of TOSV and SFSV in bat populations.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses

  • Calistri, Arianna
  • Montserrat Pulido, Núria
  • Mirazimi, Ali
  • Lolli, Marco Lucio
  • Parolin, Cristina
  • Luganini, Anna
  • Mognetti, Barbara
  • Elder, Elizabeth
  • Sibille, Giulia
  • Conciatori, Valeria
  • Vecchio, Claudia del
  • Sainas, Stefano
  • Boschi, Donatella
Although coronaviruses (CoVs) have long been predicted to cause zoonotic diseases and pandemics with high probability, the lack of effective anti-pan-CoVs drugs rapidly usable against the emerging SARS-CoV-2 actually prevented a promptly therapeutic intervention for COVID-19. Development of host-targeting antivirals could be an alternative strategy for the control of emerging CoVs infections, as they could be quickly repositioned from one pandemic event to another. To contribute to these pandemic preparedness efforts, here we report on the broad-spectrum CoVs antiviral activity of MEDS433, a new inhibitor of the human dihydroorotate dehydrogenase (hDHODH), a key cellular enzyme of the de novo pyrimidine biosynthesis pathway. MEDS433 in-hibited the in vitro replication of hCoV-OC43 and hCoV-229E, as well as of SARS-CoV-2, at low nanomolar range. Notably, the anti-SARS-CoV-2 activity of MEDS433 against SARS-CoV-2 was also observed in kidney organoids generated from human embryonic stem cells. Then, the antiviral activity of MEDS433 was reversed by the addition of exogenous uridine or the product of hDHODH, the orotate, thus confirming hDHODH as the specific target of MEDS433 in hCoVs-infected cells. Taken together, these findings suggest MEDS433 as a potential candidate to develop novel drugs for COVID-19, as well as broad-spectrum antiviral agents exploitable for future CoVs threats.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods

  • Ginex, Tiziana
  • Garaigorta, Urtzi
  • Ramírez, David
  • Castro, Victoria
  • Nozal, Vanesa
  • Maestro, Inés
  • Garcia-Carceles, Javier
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Gastaminza, Pablo
  • Gil, Carmen
The unprecedent situation generated by the COVID-19 global emergency has prompted scientists around the world to actively work to fight against this pandemic. In this sense, it is remarkable the number of drug repurposing efforts trying to shed light into the COVID-19 patients treatment. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. A successful combination of a multi-target virtual screening approach focused on host-based targets related to viral entry and experimental evaluation of the antiviral activity of selected compounds has been carried out. As a result, three different potentially repurposable drugs interfering with viral entry, cepharantine, imatinib and efloxate, have been identified., Funding from CSIC (201980E024, 202020E103 and PIE-RD-COVID-19 ref. E202020E079), EVA (European Virus Archive; grant agreement No 871029), FONDECYT grant Nº 11180604 and CONICYT-PCI grant Nº REDES190074 is acknowledged. Dr. R. Molenkamp (Erasmus University Medical Center, Rotterdam, Netherlands; participant of the EVA-GLOBAL project) is acknowledged for the SARS32 CoV-2 strain NL/2020 virus. Dr. F. L. (Inserm-Lyon) is acknowledged for the materials required to produce retroviral pseudotypes, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice, MVA-based vaccine candidates against SARS-CoV-2

  • García-Arriaza, Juan
  • Garaigorta, Urtzi
  • Pérez Ramírez, Patricia
  • Lázaro-Frías, Adrián
  • Zamora, Carmen
  • Gastaminza, Pablo
  • Fresno, Carlos del
  • Casasnovas, José María
  • Sorzano, Carlos Óscar S.
  • Sancho, David
  • Esteban, Mariano
This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic., Vaccines against SARS-CoV-2, the causative agent of the COVID-19 pandemic, are urgently needed. We developed two COVID-19 vaccines based on modified vaccinia virus Ankara (MVA) vectors expressing the entire SARS-CoV-2 spike (S) protein (MVA-CoV2-S); their immunogenicity was evaluated in mice using DNA/MVA or MVA/MVA prime/boost immunizations. Both vaccines induced robust, broad and polyfunctional S-specific CD4+ (mainly Th1) and CD8+ T-cell responses, with a T effector memory phenotype. DNA/MVA immunizations elicited higher T-cell responses. All vaccine regimens triggered high titers of IgG antibodies specific for the S, as well as for the receptor-binding domain; the predominance of the IgG2c isotype was indicative of Th1 immunity. Notably, serum samples from vaccinated mice neutralized SARS-CoV-2 in cell cultures, and those from MVA/MVA immunizations showed a higher neutralizing capacity. Remarkably, one or two doses of MVA-CoV2-S protect humanized K18-hACE2 mice from a lethal dose of SARS-CoV-2. In addition, two doses of MVA-CoV2-S confer full inhibition of virus replication in the lungs. These results demonstrate the robust immunogenicity and full efficacy of MVA-based COVID-19 vaccines in animal models and support its translation to the clinic., This research was supported by Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII), Fondo COVID-19 grant COV20/00151 and Fondo Supera COVID-19 (Crue Universidades-Banco Santander) (to J.G.-A.), CSIC grant 2020E84, Ferrovial and Mapfre donations (to M.E.) and Fondo Solidario Juntos, Banco de Santander (to D.S.). This publication was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 871029., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Label-free plasmonic biosensor for rapid, quantitative, and highly sensitive COVID-19 serology: implementation and clinical validation

  • Calvo-Lozano, Olalla
  • Sierra, Miquel
  • Soler, María
  • Estévez, M. Carmen
  • Chiscano- Camón, Luis
  • Ruiz-Sanmartín, Adolfo
  • Ruiz-Rodriguez, Juan Carlos
  • Ferrer, Ricard
  • González-López, Juan José
  • Esperalba, Juliana
  • Fernández-Nava, Candela
  • Bueno, Leticia
  • López-Aladid, Rubén
  • Torres, Antoni
  • Fernández-Barat, Laia
  • Attoumani, Sarah
  • Charrel, Remi
  • Coutard, Bruno
  • Lechuga, Laura M.
Serological tests are essential for the control and management of COVID-19 pandemic, not only for current and historical diagnostics but especially for surveillance, epidemiological, and acquired immunity studies. Clinical COVID-19 serology is routinely performed by enzymatic or chemiluminescence immunoassays (i.e., ELISA or CLIA), which provide good sensitivities at the expense of relatively long turnaround times and specialized laboratory settings. Rapid serological tests, based on lateral flow assays, have also been developed and widely commercialized, but they suffer from limited reliability due to relatively low sensitivity and specificity. We have developed and validated a direct serological biosensor assay employing proprietary technology based on Surface Plasmon Resonance (SPR). The biosensor offers a rapid -less than 15 min- identification and quantification of SARS-CoV-2 antibodies directly in clinical samples, without the need of any signal amplification. The portable plasmonic biosensor device employs a custom-designed multi-antigen sensor biochip, combining the two main viral antigens (RBD peptide and N protein), for simultaneous detection of human antibodies targeting both antigens. The SPR serology assay reaches detection limits in the low ng mL-1 range employing polyclonal antibodies as standard, which are well below the commonly detected antibody levels in COVID-19 patients. The assay has also been implemented employing the first WHO approved anti-SARS-CoV-2 immunoglobulin standard. We have carried out a clinical validation with COVID-19 positive and negative samples (n=120) that demonstrates the excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor device as an accurate, robust, and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the management of COVID-19 patients and for the evaluation of immunological status during vaccination, treatment or in front of emerging variants., H2020 Research and Innovation Programme of the European Commission Project, No. 101003544 Spanish Research Agency (AEI, grant no. SEV-2017-0706AEI, grant no. SEV-2017-0706) Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF)BES-2017-080527 GENCAT-DGRIS COVID EU H2020 Programme (644956) Plan Nacional de I+D+i 2013-2016 ISCIII- Ministerio de Ciencia e Innovación, Vall d’Hebron University Hospital Biobank PT17/0015/0047 European Virus Archive GLOBAL (EVA-GLOBAL) EU Horizon 2020 (grant agreement No. 871029) Fundació Glòria Soler for COVIDBANK collection Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

SARS-CoV-2 fears green: the chlorophyll catabolite Pheophorbide a is a potent antiviral

  • Jiménez-Alemán, G. H.
  • Castro, Victoria
  • Longdaitsbehere, Addis
  • Gutiérrez-Rodríguez, Marta
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Solano, Roberto
The SARS-CoV-2 pandemic is having devastating consequences worldwide. Although vaccination advances at good pace, effectiveness against emerging variants of the virus is unpredictable. The virus has displayed a remarkable resistance to treatments and no drugs have been proved fully effective against Covid-19. Thus, despite the international efforts, there is still an urgent need for new potent and safe antivirals against SARS-CoV-2. Here we exploited the enormous potential of plant metabolism, in particular the bryophyte Marchantia polymorpha, and following a bioactivity-guided fractionation and mass-spectrometry approach, identified a potent SARS-CoV-2 antiviral. We found that the chlorophyll derivative Pheophorbide a (PheoA), a natural porphyrin similar to animal Protoporphyrin IX, has an extraordinary antiviral activity against SARS-CoV-2 preventing infection of cultured monkey and human cells, without noticeable citotoxicity. We also show that PheoA prevents coronavirus entry into the cells by directly targeting the viral particle. Besides SARS-CoV-2, PheoA also displayed a broad-spectrum antiviral activity against (+)strand RNA viral pathogens such as HCV, West Nile, and other coronaviruses, but not against (-)strand RNA viruses, such as VSV. Our results indicate that PheoA displays a remarkable potency and a satisfactory therapeutic index, and suggest that it may be considered as a potential candidate for antiviral therapy against SARS-CoV-2. Moreover, PheoA adds to remdesivir's efficiency and is currently employed in photoactivable cancer therapies in humans., This research was funded by CSIC (PIE-RD-COVID-19 ref 202040E236 to R.S., PIE-RD COVID-19 ref. E202020E079 to P.G and U.G, and CSIC-CoV19-153 ref PIE-202080E221 to M.G-R.). Funding from EVA (European Virus Archive; grant agreement No 871029) is gratefully acknowledge. GH. J-A. was supported by the Deutsche Forschungsgemeinschaft (Individual Research Grant JI 241/2-1)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target

  • García-Dorival, Isabel
  • Cuesta-Geijo, Miguel Ángel
  • Barrado-Gil, Lucía
  • Galindo Barreales, Inmaculada
  • Garaigorta, Urtzi
  • Urquiza, Jesús
  • Puerto, Ana del
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Gastaminza, Pablo
  • Gil, Carmen
  • Alonso Martí, Covadonga
10 p.-4 fig., Niemann-Pick type C1 (NPC1) receptor is an endosomal membrane protein that regulates intracellular cholesterol traffic. This protein has been shown to play an important role for several viruses. It has been reported that SARS-CoV-2 enters the cell through plasma membrane fusion and/or endosomal entry upon availability of proteases. However, the whole process is not fully understood yet and additional viral/host factors might be required for viral fusion and subsequent viral replication. Here, we report a novel interaction between the SARS-CoV-2 nucleoprotein (N) and the cholesterol transporter NPC1. Furthermore, we have found that some compounds reported to interact with NPC1, carbazole SC816 and sulfides SC198 and SC073, were able to reduce SARS-CoV-2 viral infection with a good selectivity index in human cell infection models. These findings suggest the importance of NPC1 for SARS-CoV-2 viral infection and a new possible potential therapeutic target to fight against COVID-19., This research was partially supported through “La Caixa” Banking Foundation (LCF/PR/HR19/52160012), Instituto de Salud Carlos III (ISCIII–COV20/01007), the Spanish Ministry of Science and Innovation (RTI2018-097305-R-I00), CSIC (PIE-RD-COVID-19 refs. E201980E024 and E202020E079) and the European Union-NextGenerationEU. EVA (European Virus Archive; grant agreement No 871029)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral

  • Jiménez-Alemán, G. H.
  • Castro, Victoria
  • Longdaitsbehere, Addis
  • Gutiérrez-Rodríguez, Marta
  • Garaigorta, Urtzi
  • Solano, Roberto
  • Gastaminza, Pablo
SARS-CoV-2 pandemic is having devastating consequences worldwide. Although vaccination advances at good pace, effectiveness against emerging variants is unpredictable. The virus has displayed a remarkable resistance to treatments and no drugs have been proved fully effective against COVID-19. Thus, despite the international efforts, there is still an urgent need for new potent and safe antivirals against SARS-CoV-2. Here, we exploited the enormous potential of plant metabolism using the bryophyte Marchantia polymorpha L. and identified a potent SARS-CoV-2 antiviral, following a bioactivity-guided fractionation and mass-spectrometry approach. We found that the chlorophyll derivative Pheophorbide a (PheoA), a porphyrin compound similar to animal Protoporphyrin IX, has an extraordinary antiviral activity against SARS-CoV-2, preventing infection of cultured monkey and human cells, without noticeable cytotoxicity. We also show that PheoA targets the viral particle, interfering with its infectivity in a dose- and time-dependent manner. Besides SARS-CoV-2, PheoA also displayed a broad-spectrum antiviral activity against enveloped RNA viral pathogens such as HCV, West Nile, and other coronaviruses. Our results indicate that PheoA displays a remarkable potency and a satisfactory therapeutic index, which together with its previous use in photoactivable cancer therapy in humans, suggest that it may be considered as a potential candidate for antiviral therapy against SARS-CoV-2., This research was funded by CSIC (PIE-RD-COVID-19 ref 202040E236 to R.S., PIE-RDCOVID-19 ref. E202020E079 to P.G. and U.G., and CSIC-CoV19-153 ref PIE-202080E221 to M.G.- R.), EVA (European Virus Archive; grant agreement No 871029 to P.G.) and the European UnionNextGenerationEU. G.H.J.-A. was supported by the Deutsche Forschungsgemeinschaft (Individual Research Grant JI 241/2-1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron

  • Casasnovas, José María
  • Margolles, Yago
  • Noriega, María A.
  • Guzmán, María
  • Arranz, Rocío
  • Melero, Roberto
  • Casanova, Mercedes
  • Corbera, Juan Alberto
  • Jiménez de Oya, Nereida
  • Gastaminza, Pablo
  • Garaigorta, Urtzi
  • Saiz Calahorra, Juan Carlos
  • Martín-Acebes, M. A.
  • Fernández, Luis Ángel
The emergence of SARS-CoV-2 variants that escape from immune neutralization are challenging vaccines and antibodies developed to stop the COVID-19 pandemic. Thus, it is important to establish therapeutics directed toward multiple or specific SARS-CoV-2 variants. The envelope spike (S) glycoprotein of SARS-CoV-2 is the key target of neutralizing antibodies (Abs). We selected a panel of nine nanobodies (Nbs) from dromedary camels immunized with the receptor-binding domain (RBD) of the S, and engineered Nb fusions as humanized heavy chain Abs (hcAbs). Nbs and derived hcAbs bound with subnanomolar or picomolar affinities to the S and its RBD, and S-binding cross-competition clustered them in two different groups. Most of the hcAbs hindered RBD binding to its human ACE2 (hACE2) receptor, blocked cell entry of viruses pseudotyped with the S protein and neutralized SARS-CoV-2 infection in cell cultures. Four potent neutralizing hcAbs prevented the progression to lethal SARS-CoV-2 infection in hACE2-transgenic mice, demonstrating their therapeutic potential. Cryo-electron microscopy identified Nb binding epitopes in and out the receptor binding motif (RBM), and showed different ways to prevent virus binding to its cell entry receptor. The Nb binding modes were consistent with its recognition of SARS-CoV-2 RBD variants; mono and bispecific hcAbs efficiently bound all variants of concern except omicron, which emphasized the immune escape capacity of this latest variant., This work was partially funded by Ministerio de Ciencia e Innovación (MICIN; https://www.ciencia.gob.es/) and the Spanish Research Council (CSIC; https://www.csic.es/) under grants PIE-RD-COVID 19 (No 202020E079) and PTI+ Salud Global REC_EU (No SGL 2103051, NextGenerationEU) to LF, JMC, PG, and UG, and (No SGL 2103053, NextGenerationEU) to MM-A. This study was partially conducted within the CSIC Antiviral Screening Network, an infrastructure supported by NextGeneration EU funds (https://ec.europa.eu/info/strategy/recovery-plan-europe_es) from the European Union and the European Virus Archive Global (EVag) of the European Union’s Horizon 2020 (https://ec.europa.eu/programmes/horizon2020/en/home) research and innovation programme (No 871029) to PG and UG. EM facilities of CNB-CSIC were supported by Ministerio de Ciencia e Innovación (MICIN; https://www.ciencia.gob.es/), EU-FEDER (https://ec.europa.eu/regional_policy/es/funding/erdf/) CRIOMECORR project (ESFRI-2019-01-CSIC-16). JMC access to the European Synchrotron Radiation Facility (ESRF) CM01 line through the Iberian-BAG, and to the Instruct Image Processing Center (I2PC, http://i2pc.es/) by projects PID16168 and PID14989. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo-Lozano, Olalla
  • Sierra, Miquel
  • Soler, María
  • Estévez, M. Carmen
  • Chiscano- Camón, Luis
  • Ruiz-Sanmartín, Adolfo
  • Ruiz-Rodriguez, Juan Carlos
  • Ferrer, Ricard
  • González-López, Juan José
  • Esperalba, Juliana
  • Fernández-Nava, Candela
  • Bueno, Leticia
  • López-Aladid, Rubén
  • Torres, Antoni
  • Fernández-Barat, Laia
  • Attoumani, Sarah
  • Charrel, Remi
  • Coutard, Bruno
  • Lechuga, Laura M.
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Broad virus inactivation using inorganic micro/nano-particulate materials

  • Rius-Rocabert, Sergio
  • Arranz-Herrero, Javier
  • Fernández-Valdés, Adolfo
  • Marciello, Marzia
  • Moreno, Sandra
  • Llinares-Pinel, Francisco
  • Presa, Jesús
  • Hernández-Alcoceba, Rubén
  • López-Píriz, Roberto
  • Torrecillas, Ramón
  • García, Antonia
  • Brun Torres, Alejandro
  • Filice, Marco
  • Moya, J. S.
  • Cabal, Belén
  • Nistal-Villán, Estanislao
Inorganic materials can provide a set of tools to decontaminate solid, liquid or air containing viral particles. The use of disinfectants can be limited or not practical in scenarios where continuous cleaning is not feasible. Physicochemical differences between viruses raise the need for effective formulations for all kind of viruses. In the present work we describe two types of antimicrobial inorganic materials: i) a novel soda-lime glass (G3), and ii) kaolin containing metals nanoparticles (Ag or CuO), as materials to disable virus infectivity. Strong antiviral properties can be observed in G3 glass, and kaolin-containing nanoparticle materials showing a reduction of viral infectivity close to 99%. in the first 10 ​min of contact of vesicular stomatitis virus (VSV). A potent virucidal activity is also present in G3 and kaolin containing Ag or CuO nanoparticles against all kinds of viruses tested, reducing more than 99% the amount of HSV-1, Adenovirus, VSV, Influenza virus and SARS-CoV-2 exposed to them. Virucidal properties could be explained by a direct interaction of materials with viruses as well as inactivation by the presence of virucidal elements in the material lixiviates. Kaolin-based materials guarantee a controlled release of active nanoparticles with antiviral activity. Current coronavirus crisis highlights the need for new strategies to remove viruses from contaminated areas. We propose these low-cost inorganic materials as useful disinfecting antivirals in the actual or future pandemic threats., This research was performed with support from The Spanish National Research Council (CSIC) (Project No 202060E109). M.F. is grateful to the Comunidad Autonoma de Madrid for research project No. 2017-T1/BIO-4992 (“Atracción de Talento” Action) cofunded by Universidad Complutense de Madrid. This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program ​under grant agreement 871029. S. R.-R. was supported by the the FPI fellowship funded by Universidad San Pablo CEU. J.A-H. was supported by the PFIS fellowship co-funded by the FEDER/FSE and the ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Identification of small molecules with virus growth enhancement properties

  • García-Murria, Maria Jesús
  • Gadea-Salom, Laura
  • Moreno, Sandra
  • Zaragoza, Óscar
  • Brun Torres, Alejandro
  • Mingarro, Ismael
  • Martínez-Gil, Luis
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the pandemic disease known as coronavirus disease 2019 (COVID-19). COVID-19 vaccines were developed at record speed and were authorized approximately a year after the original outbreak. This fast response saved the lives of countless individuals and reduced the disease burden of many more. The experience has served as a reminder of the necessity to implement solid vaccine development platforms and fast production pipelines. Manufacturing vaccines for enveloped viruses, including some SARS-CoV-2 vaccines, often relies on the production of large quantities of viruses in vitro. Thus, speeding up or increasing virus production would expedite vaccine development. With this objective in mind, we established a high throughput screening (HTS) to identify small molecules that enhance or speed up host-virus membrane fusion. Among the HTS hits, we identified that ethynylestradiol augments SARS-CoV-2 fusion activity in both the absence and presence of TMPRSS2. Furthermore, we confirmed that ethynylestradiol can boost the growth of not only SARS-CoV-2 but also Influenza A virus in vitro. A small molecule with these characteristics could be implemented to improve vaccines production., We thank the Generalitat Valenciana (PROMETEO/2019/065) and the Spanish Ministry of Science and Innovation (PID2020-119111GB-I00). We thank P. Selvi for excellent technical assistance. O.Z. is funded by grant PID2020-114546RB-I00 from National Research Agency (Spanish Ministry for Science and Innovation). This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement 871029., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor

  • Ruiz-Vega, Gisela
  • Soler, María
  • Estévez, M. Carmen
  • Ramirez-Priego, Patricia
  • Pazos, Martalu D.
  • Noriega, María A.
  • Margolles, Yago
  • Francés-Gómez, Clara
  • Geller, Ron
  • Matusali, Giulia
  • Colavita, Francesca
  • Di Caro, Antonino
  • Casasnovas, José María
  • Fernández, Luis Ángel
  • Lechuga, Laura M.
The coronavirus (CoV) disease 2019 (COVID-19) is expected to become endemic in the coming years, meaning that the worldwide society shall be prepared to routinely manage the highly contagious respiratory SARS-CoV-2. A rapid and early diagnosis of the SARS-CoV-2 infection is crucial for controlling the spread of the disease, interrupting the transmission chain, and providing timely medical attention to patients. We introduce an innovative nanophotonic biosensor for the quantitative detection of viral particles in less than 20 minutes total assay time. The nanosensor, based on the bimodal waveguide (BiMW) interferometric technology, has been functionalized with novel bioengineered nanobodies (Nb) targeting the SARS-CoV-2 receptor-binding domain (RBD). Our approach relies on the direct capture of the viral particles, and the optimized methodology allows the detection of the SARS-CoV-2 virus with outstanding sensitivity, below 200 TCID50 per mL, being able to provide accurate viral load determination within a broad dynamic range (102–106 TCID50 per mL). Both the nanobodies and the sensor nanotechnology can be produced at a large scale with highly-efficient cost-effective procedures, and they are being integrated into a user-friendly point-of-care device for multiplexed and decentralized operation. The implementation of this unique biosensor in primary care assistance, hospitals, pharmacies, or private laboratories could greatly aid in the relief and descongestion of the sanitary systems and the clinical and social management of COVID-19., This work has been mainly funded by the H2020 Research and Innovation Program of the European Commission (H2020-SC1-PHE-Coronavirus-2020, CONVAT No 101003544) and by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global – Iniciativa Estratégica de Diagnóstico). The ICN2 is funded by the CERCA Program/Generalitat de Catalunya and supported by the Severo Ochoa Centers of Excellence program, funded by the Spanish Research Agency (AEI, grant SEV-2017-0706). Work in CNB-CSIC was funded by the Spanish Ministry of Science and Innovation (MICIN) and the Spanish Research Council (CSIC) under grants PIE-RD-COVID 19 (No 202020E079) and PTI Salud Global REC_EU (No SGL 2103051, NextGenerationEU). Work at I2SysBio was funded by Ayudas de concesión directa a soluciones científico-innovadoras directamente relacionadas con la lucha contra la Covid-19 grant from the Generalitat Valenciana, Spanish National Research Council grant CSIC-COV19-082/104, Fondo Supera Covid-19 grant BlockAce, and European Commission – NextGenerationEU to Ron Geller. INMI received funds for this study from the Ministero della Salute (Ricerca Corrente - linea 1), the European Commission – Horizon 2020 (EU project 101003544 – CoNVat) and the European Virus Archive – GLOBAL (grants no. 653316 and no. 871029), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy

  • Batool, Razia
  • Soler, María
  • Colavita, Francesca
  • Fabeni, Lavinia
  • Matusali, Giulia
  • Lechuga, Laura M.
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 102 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC50) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer., Financial support is acknowledged from the SensCELL project (Ref. No. PGC-2018-099870), funded by the Spanish Ministry of Science and Innovation (MCIN), the Spanish Research Agency (AEI), and the European Regional Development Fund (ERDF), and from the CONVAT project (Ref. 101003544), funded by the H2020 Research and Innovation Programme of the European Commission (H2020-SC1-PHE-Coronavirus-2020). RB acknowledges the economic support (Ref. PRE2019- 089357) from MCIN and AEI linked to the project SEV-2017-0706-19-4. MS acknowledges the economic support of the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. INMI also acknowledges funding from the European Virus Archive – GLOBAL (Grant No. 871029). The ICN2 is supported by the CERCA programme (Generalitat de Catalunya) and the Severo Ochoa Centres of Excellence programme, funded by the AEI (Grant. No. SEV-2017-0706)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of small molecules capable of enhancing viral membrane fusion

  • García-Murria, Maria Jesús
  • Gadea-Salom, Laura
  • Moreno, Sandra
  • Rius-Salvador, Marina
  • Zaragoza, Óscar
  • Brun Torres, Alejandro
  • Mingarro, Ismael
  • Martínez-Gil, Luis
12 Pág., Several approaches have been developed to analyze the entry of highly pathogenic viruses. In this study, we report the implementation of a Bimolecular Multicellular Complementation (BiMuC) assay to safely and efficiently monitor SARS-CoV-2 S-mediated membrane fusion without the need for microscopy-based equipment. Using BiMuC, we screened a library of approved drugs and identified compounds that enhance S protein-mediated cell-cell membrane fusion. Among them, ethynylestradiol promotes the growth of SARS-CoV-2 and Influenza A virus in vitro. Our findings demonstrate the potential of BiMuC for identifying small molecules that modulate the life cycle of enveloped viruses, including SARS-CoV-2., This work was supported by the Generalitat Valenciana (PROMETEO/2019/065) and grant PID2020-119111GB-I00 by MCIN/AEI/10.13039/501100011033. O.Z. is funded by grant PID2020-114546RB by MCIN/AEI/10.13039/501100011033. L.G. is the recipient of a predoctoral contract (CIACIF/2021/119) from the Generatitat Valenciana. M.R-S is the recipient of a predoctoral contract from the Spanish Ministry of Science and Innovation (PRE2021-101042 by MCIN/AEI/10.13039/501100011033). This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project which has received funding from the European Union?s Horizon 2020 research and innovation program under grant agreement 871029., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Three-Dimensional Remodeling of SARS-CoV2-Infected Cells Revealed by Cryogenic Soft X-ray Tomography

  • Castro, Victoria
  • Pérez-Berna, Ana Joaquina
  • Calvo, Gema
  • Pereiro, Eva
  • Gastaminza, Pablo
Plus-strand RNA viruses are proficient at remodeling host cell membranes for optimal viral genome replication and the production of infectious progeny. These ultrastructural alterations result in the formation of viral membranous organelles and may be observed by different imaging techniques, providing nanometric resolution. Guided by confocal and electron microscopy, this study describes the generation of wide-field volumes using cryogenic soft-X-ray tomography (cryo-SXT) on SARS-CoV-2-infected human lung adenocarcinoma cells. Confocal microscopy showed accumulation of double-stranded RNA (dsRNA) and nucleocapsid (N) protein in compact perinuclear structures, preferentially found around centrosomes at late stages of the infection. Transmission electron microscopy (TEM) showed accumulation of membranous structures in the vicinity of the infected cell nucleus, forming a viral replication organelle containing characteristic double-membrane vesicles and virus-like particles within larger vesicular structures. Cryo-SXT revealed viral replication organelles very similar to those observed by TEM but indicated that the vesicular organelle observed in TEM sections is indeed a vesiculo-tubular network that is enlarged and elongated at late stages of the infection. Overall, our data provide additional insight into the molecular architecture of the SARS-CoV-2 replication organelle., This study was funded by ALBA Synchrotron standard proposals 2022065884 and 2021024899, the Spanish National Research Council (grant number PIE-RD-COVID-19 ref E202020E079) and PID2020-115476RB-I00 funded by MCIN/AEI/10.13039/501100011033, and by “ERDF A way of making Europe” to the CNB-CSIC. This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). G.C. was initially supported by SAF2017-87846-R from the Spanish Ministry of Science, and V.C. was initially supported by PIE-RD-COVID-19. A.J.P.-B., G.C., V.C., E.P., and P.G. are part of the CoCID Consortium (cocid.eu), which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 1010171162. We acknowledge R. Molenkamp (Erasmus University Medical Center, Rotterdam, The Netherlands; participant of the EU-funded EVA-GLOBAL project, grant agreement 871029) for the SARS-CoV-2 strain NL/2020 virus, Ralf Bartenschlager lab for the SARS-CoV-2 reporter construct, L. Enjuanes (Department of Molecular and Cell Biology, CNB-CSIC) for the Vero-E6 cells, and Urtzi Garaigorta (Department of Molecular and Cell Biology, CNB-CSIC) for critically reading the manuscript. We acknowledge the outstanding technical support from the BSL3 laboratory, Advanced Microscopy, Electron Microscopy and Cryoelectron Microscopy Core facilities personnel at the CNB as well as the support of ALBA staff, in particular Andrea Sorrentino and Ricardo Valcarcel from the MISTRAL beamline., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses

  • Calistri, Arianna
  • Montserrat Pulido, Núria
  • Mirazimi, Ali
  • Lolli, Marco Lucio
  • Parolin, Cristina
  • Luganini, Anna
  • Mognetti, Barbara
  • Elder, Elizabeth
  • Sibille, Giulia
  • Conciatori, Valeria
  • Vecchio, Claudia del
  • Sainas, Stefano
  • Boschi, Donatella
Although coronaviruses (CoVs) have long been predicted to cause zoonotic diseases and pandemics with high probability, the lack of effective anti-pan-CoVs drugs rapidly usable against the emerging SARS-CoV-2 actually prevented a promptly therapeutic intervention for COVID-19. Development of host-targeting antivirals could be an alternative strategy for the control of emerging CoVs infections, as they could be quickly repositioned from one pandemic event to another. To contribute to these pandemic preparedness efforts, here we report on the broad-spectrum CoVs antiviral activity of MEDS433, a new inhibitor of the human dihydroorotate dehydrogenase (hDHODH), a key cellular enzyme of the de novo pyrimidine biosynthesis pathway. MEDS433 in-hibited the in vitro replication of hCoV-OC43 and hCoV-229E, as well as of SARS-CoV-2, at low nanomolar range. Notably, the anti-SARS-CoV-2 activity of MEDS433 against SARS-CoV-2 was also observed in kidney organoids generated from human embryonic stem cells. Then, the antiviral activity of MEDS433 was reversed by the addition of exogenous uridine or the product of hDHODH, the orotate, thus confirming hDHODH as the specific target of MEDS433 in hCoVs-infected cells. Taken together, these findings suggest MEDS433 as a potential candidate to develop novel drugs for COVID-19, as well as broad-spectrum antiviral agents exploitable for future CoVs threats.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Seroprevalence of toscana Virus and sandfly fever sicilian virus in European bat colonies measured using a neutralization test

  • Ayhan, Nazli
  • López-Roig, Marc
  • Monastiri, Abir
  • Charrel, Rémi N.
  • Serra Cobo, Jordi
Toscana phlebovirus (TOSV) and Sicilian phlebovirus (SFSV) are endemic in the Mediterranean area where they are transmitted to humans by infected sandflies. Vertebrates of several species have been postulated to act as reservoirs of these viruses, but convincing evidence is still awaited. Among them, bats have been suggested, however documented evidence is lacking. Here we tested a total of 329 bats belonging to eight species collected from twelve localities in southern Spain for the presence of neutralizing antibodies specific to TOSV and SFSV. Positive sera were detected in Schreiber's long-fingered bat (Miniopterus schreibersii), mouse-eared Myotis (Myotis myotis), European free-tailed bat (Tadarida teniotis), and common serotine (Eptesicus serotinus) with the latter showing the highest prevalence rates for SFSV (22.6%) and TOSV (10%). There was no difference between females and males. Results suggest that bats are not likely to play a major role in the natural cycle of these two sandfly-borne phleboviruses. However, large breeding colonies of bats can be used as sentinels for surveillance of the presence of such viruses in a given locality. In addition, capture-recapture studies should be initiated in order to understand better the dynamics of TOSV and SFSV in bat populations.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology, Implementation and Clinical Validation

  • Calvo Lozano, Olalla|||0000-0001-5486-2237
  • Sierra, Miquel
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Chiscano-Camón, Luis|||0000-0003-0037-0610
  • Ruiz-Sanmartin, Adolfo
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • González-López, Juanjo|||0000-0003-2419-5909
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Bueno, Leticia
  • López-Aladid, Ruben
  • Torres, Antoni|||0000-0002-8643-2167
  • Fernández Barat, Laia|||0000-0001-7528-9636
  • Attoumani, Sarah
  • Charrel, Rémi
  • Coutard, Bruno
  • Lechuga, Laura M.|||0000-0001-5187-5358
Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL -1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid and direct quantification of the SARS-CoV-2 virus with an ultrasensitive nanobody-based photonic nanosensor

  • Ruiz Vega, Gisela|||0000-0002-8438-3146
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Estévez, M. Carmen|||0000-0003-3694-7186
  • Ramirez Priego, Patricia|||0000-0001-5657-3279
  • Pazos, Martalu D.
  • Noriega, María A.
  • Margolles, Yago
  • Francés-Gómez, Clara
  • Geller, Ron
  • Matusali, Giulia
  • Colavita, Francesca
  • Caro, Antonino di
  • Casasnovas, José M.|||0000-0002-2873-6410
  • Fernández, Luis Angel
  • Lechuga, Laura M|||0000-0001-5187-5358
The coronavirus (CoV) disease 2019 (COVID-19) is expected to become endemic in the coming years, meaning that the worldwide society shall be prepared to routinely manage the highly contagious respiratory SARS-CoV-2. A rapid and early diagnosis of the SARS-CoV-2 infection is crucial for controlling the spread of the disease, interrupting the transmission chain, and providing timely medical attention to patients. We introduce an innovative nanophotonic biosensor for the quantitative detection of viral particles in less than 20 minutes total assay time. The nanosensor, based on the bimodal waveguide (BiMW) interferometric technology, has been functionalized with novel bioengineered nanobodies (Nb) targeting the SARS-CoV-2 receptor-binding domain (RBD). Our approach relies on the direct capture of the viral particles, and the optimized methodology allows the detection of the SARS-CoV-2 virus with outstanding sensitivity, below 200 TCID50 per mL, being able to provide accurate viral load determination within a broad dynamic range (102-106 TCID50 per mL). Both the nanobodies and the sensor nanotechnology can be produced at a large scale with highly-efficient cost-effective procedures, and they are being integrated into a user-friendly point-of-care device for multiplexed and decentralized operation. The implementation of this unique biosensor in primary care assistance, hospitals, pharmacies, or private laboratories could greatly aid in the relief and descongestion of the sanitary systems and the clinical and social management of COVID-19.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy

  • Batool, Razia|||0000-0001-6864-5655
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Colavita, Francesca
  • Fabeni, Lavinia|||0000-0002-2975-8611
  • Matusali, Giulia
  • Lechuga, Laura M|||0000-0001-5187-5358
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 10 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Broad virus inactivation using inorganic micro/nano-particulate materials

  • Rius Rocabert, S.
  • Arranz Herrero, J.
  • Fernández Valdés, A.
  • Marciello, M.
  • Moreno, S.
  • Llinares Pinel, F.
  • Presa, J.
  • Hernández Alcoceba, R.
  • López Píriz, R.
  • Torrecillas San Millán, Ramón|||0000-0003-3856-0217
This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 871029., Rius-Rocabert S, Arranz-Herrero J, Fernández-Valdés A, Marciello M, Moreno S, Llinares-Pinel F, Presa J, Hernandez-Alcoceba R, López-Píriz R, Torrecillas R, García A, Brun A, Filice M, Moya JS, Cabal B, Nistal-Villan E
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Label-Free Plasmonic Biosensor for Rapid, Quantitative, and Highly Sensitive COVID-19 Serology: Implementation and Clinical Validation

  • Calvo Lozano, Olalla
  • Sierra Montoya, Miquel
  • Soler, Maria
  • Estevez, M. Carmen
  • Chiscano Camon, Luis Silvestre
  • Ruiz Sanmartin, Adolfo
  • Ruiz Rodriguez, Juan Carlos
  • Ferrer Roca, Ricard
  • Gonzalez Lopez, Juan Jose
  • Esperalba Esquerra, Juliana
  • Fernandez Naval, Candela
COVID-19; Biosensor plasmónico; Serología, COVID-19; Biosensor plasmònic; Serologia, COVID-19; Plasmonic biosensor; Serology, Serological tests are essential for the control and management of COVID-19 pandemic (diagnostics and surveillance, and epidemiological and immunity studies). We introduce a direct serological biosensor assay employing proprietary technology based on plasmonics, which offers rapid (<15 min) identification and quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in clinical samples, without signal amplification. The portable plasmonic device employs a custom-designed multiantigen (RBD peptide and N protein) sensor biochip and reaches detection limits in the low ng mL–1 range employing polyclonal antibodies. It has also been implemented employing the WHO-approved anti-SARS-CoV-2 immunoglobulin standard. A clinical validation with COVID-19 positive and negative samples (n = 120) demonstrates its excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor as an accurate and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the disease management and for the evaluation of immunological status during vaccination or treatment., ICN2 and UVE acknowledge financial support from H2020 Research and Innovation Programme of the European Commission (H202-SC1-PHE-Coronavirus-2020, CONVAT Project, No. 101003544). The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). ICN2 group is very grateful to EPI Industries (Barcelona, Spain) for its kind donation supporting our research in COVID-19. O.C.-L. acknowledges the economic support from the Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF) (ref. BES-2017-080527) linked to the TEC 2016-78515-R project Predict. A part of the work was supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the EU Horizon 2020 (grant agreement No. 871029). A.T. and L.F.-B. acknowledge financial support from GENCAT-DGRIS COVID. We are indebted to all the patients who accepted to participate contributing to science advancement. We are indebted to the HCB-IDIBAPS Biobank for the human samples and data procurement and to the Fundació Glòria Soler for its support to the COVIDBANK collection. We thank the IDIBAPS Biobank for its valuable contribution to sample processing and storage. The authors acknowledge the EU Horizon 2020 Program under grant agreement no. 644956 (RAIS project) for funding the Hospital Vall d’Hebron Biobank. The VHIR-HUVH is supported by Plan Nacional de I + D + i 2013-2016 and ISCIII-Ministerio de Ciencia e Innovación, and Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003)─cofinanced by European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014. Part of the samples and data from patients included in this study were provided by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. The authors kindly appreciate the generous donation of samples and clinical data of the donors of the Sepsis Bank of HUVH Biobank and COVID-19 patients attended at HUVH.